US/UK/Canada

Share

Pick a time period -
Tags ( Active)

New Head of Investor Relations at Nobel Biocare

New Head of Investor Relations at Nobel Biocare As of January 5, 2004 Suha Demokan (37) will join Nobel Biocare as the Head of Investor Relations. The Investor Relations function will be enhanced to address the increasing needs of stock exchanges, shareholders, investors, financial analysts and the media. This function will report directly to the Chief Executive Officer Heliane Canepa. Suha Demokan has been with Centerpulse AG in various financial positions for over 13 years, most recently as Head of Investor Relations. He will be located in Zurich, while Gunilla Ekholtz remains in Investor

Interim Report 3, 2003

Interim Report 3, January - September 2003 22 October 2003 Nobel Biocare Group Positive growth momentum and continued profitability increase in Q3 2003 Revenue was up 17.4% in local currencies excluding sales of the discontinued Gore products in the third quarter; 14.3% in local currencies including Gore products. Profit from operations (EBIT), before restructuring expenses in 2002, increased by 15.7% and amounted to EUR 16.2 million in the third quarter. During the first nine months of 2003, revenue increased by 16.7% in local currencies excluding sales of the discontinued Gore products

Nobel Biocare to launch NobelPerfect implant

Nobel Biocare to launch the NobelPerfecttm dental implant for natural esthetics Nobel Biocare, the world leader in innovative dental solutions, will this week introduce a unique patented implant called NobelPerfecttm at the American Academy of Oral and Maxillofacial Surgeons (AAOMS) scientific meeting in Orlando, USA. NobelPerfecttm is the first implant that effectively eliminates the "black triangle" often encountered with conventional implants. This revolutionary "scalloped" profile implant is primarily indicated in cases where a patient has teeth missing in the esthetic region of the

Interim Report 2, Jan-June 2003

Interim Report 2, January - June 2003 13 August 2003 Nobel Biocare Group Strong Sales and Profitability Growth in the Second Quarter - Revenue was up 19.8% in local currencies in the Second Quarter; 20.6% in local currencies excluding sales of the discontinued Gore products. Profit from operations (EBIT), before restructuring expenses in 2002, increased by 27.6% and amounted to EUR 21.7 million in the Second Quarter 2003. - In the First Half of 2003, revenue increased by 15.8% in local currencies and amounted to EUR 165.3 million. Excluding sales of the discontinued Gore products, revenue

Nobel Biocare to end distribution of Gore Regenerative Products

Nobel Biocare to end distribution of Gore Regenerative Products Nobel Biocare will end distributing the regenerative dental products from W.L.Gore & Associates, Inc., May 31, 2003. Sales of the Gore regenerative products amounts to approximately two percent of Nobel Biocare's total sales. "Nobel Biocare considers regenerative techniques as an important procedure for some indications of dental implant therapy and the company is involved in several R&D ventures in this area. We are now free to pursue other opportunities in the regenerative field ", says Heliane Canepa, President & CEO of

Press release Nobel Biocare Holding AG

1st Annual General Meeting in Nobel Biocare Holding AG, 24 April 2003 in Zurich, Switzerland The Annual General Meeting on 24 April, 2003, approved a dividend of CHF 0.79 gross per bearer share of CHF 2.-- nom. on the share capital entitled to dividends = total CHF 19.842.654.--. The dividen will be paid on 29 April, 2003, which is also the ex- dividend day. The following board members were re-elected: Jan Ekberg, Hansjörg Graf, Jan Kvarnström and Ernst Zaengerle for a one-year term of office. Rolf Soiron was elected as new board member for a one-year term of office. At the board meeting

Q1 Report, 2003

Interim Report 1, January - March 2003 24 April 2003 Nobel Biocare Holding AG Group * Net profit increased by 38.7% to EUR 14.7 million in the first quarter confirming that further profitability improvements were achieved in the production related processes and that operating expenses were kept under control. * Revenue increased by 11.8% (currency-adjusted) to EUR 79.8 million in the first quarter. After a soft January, with major activities focused on internal sales training, revenue growth has improved from February onwards. Revenue trends are especially strong in North America and Asia

Invitation AGM 2 April 2003

Nobel Biocare Holding AG, Zurich Invitation to the 1st Annual General Meeting in Nobel Biocare Holding AG, 24 April 2003 in Zurich, Switzerland The Annual General Meeting will be held on Thursday, April 24, 2003, at 10:30 a.m. at the UBS-Konferenzgebäude, Grünenhof, Nüschelerstrasse 9, 8001 Zurich, Switzerland, Auditorium on the 2nd floor, (doors open at 9:30 a.m.) Please note that the Agenda and the Proposals of the Board of Directors were drawn up in German and that the text below is a translation. Agenda and Proposals of the Board of Directors 1. Approval of the annual report, annual

Compulsory purchase of minority shares in Nobel Biocare AB (publ)

Compulsory purchase of minority shares in Nobel Biocare AB (publ) Nobel Biocare Holding AG (a Swiss company) acquired more than 98 per cent of the total number of shares and votes in Nobel Biocare AB (publ) (a Swedish company) in 2002. In order to be able to purchase the remaining shares, Nobel Biocare Holding AG has transferred all of it shares in Nobel Biocare AB to a wholly owned Swedish subsidiary, Nobel Biocare Sverige AB. (Compulsory purchase of shares in a Swedish company requires that the buyer is also a Swedish company) The compulsory purchase procedure was initiated on January 16,

Capital Markets Day at Nobel Biocare

Capital Markets Day at Nobel Biocare Nobel Biocare has invited to a Capital Markets Day in Gothenburg, Sweden, today. Two live operations featuring the latest achievements in dental implants will be the highlights of the day at the Nobel Biocare Training Center. Participants will be able to witness immediate single-tooth replacement carried out with the new Replace Select products. They will also be given a glimpse of the product pipeline including live surgery featuring the "Teeth-In-An-Hour" concept. One patient will have her damaged tooth extracted and replaced with a single Replace

Nobel Biocare launches its new product assortment

Nobel Biocare launches its new product assortment On November 1, Nobel Biocare started to deliver its new product assortment for dental implants. As a result of a total re-engineering process, the product offer has been reduced from 1,900 to 800 articles also including 380 new products. This is in line with the timetable set out one year ago, when Nobel Biocare announced its plans for a new market strategy. "With the introduction of this new product offer, we have completed the integration of Nobel Biocare's dental businesses and thereby provided a platform for further growth and

Interim Report 3, January - September 2002

Interim Report 3, January - September 2002 23 October 2002 Nobel Biocare Holding AG Group Nobel Biocare is experiencing an increasing currency-adjusted growth trend. Total sales amounted to SEK 2 075.8 million (11.5% currency- adjusted growth). In Q3 2002, sales amounted to SEK 618.0 million (12.8% currency-adjusted growth). North America reports an improving growth trend, while the European markets show mixed developments. Japan maintains the strong sales growth. Operating income before non-recurring items increased by 45.2% to SEK 427.0 million, and Operating income rose by 34.6% to SEK

Nobel Biocare is now entering a new customer segment in order to meet increased patient demand for dental implants

Nobel Biocare is now entering a new customer segment in order to meet increased patient demand for dental implants The new Nobel Biocare was presented today by company CEO Heliane Canepa at the EAO Scientific Meeting (European Academy of Osseointegration) in Brussels for an audience of 500 leading dental implant specialist. During the past year, significant changes have taken place in every area of Nobel Biocare in order to prepare the company for a new level of growth. This growth will be achieved by entering a new rapidly expanding market segment comprising general practitioners. These

Interim Report 2, January - June 2002

Interim Report 2, January - June 2002 14 August 2002 Nobel Biocare Holding AG Group - Total sales increased by 11% (11% currency adjusted) to SEK 1 457.8 million. In Q2 2002, sales increased by 7% (11% currency adjusted) to SEK 728.9 million. Sales performance in Q2 was not impacted by any price changes. - Japan continued to experience positive sales trends. Notable improvements were recorded in the second quarter in Germany, Belgium and the Netherlands. - Operating income before non-recurring items increased by 39% to SEK 293.1 million, and Operating income by 13% to SEK 239.7 million. In

After the extended acceptance period ending July 9 2002, Nobel Biocare Holding AG now owns approximately 99% of the shar

After the extended acceptance period ending July 9 2002, Nobel Biocare Holding AG now owns approximately 99% of the shares of Nobel Biocare AB Owning 99% of the shares in Nobel Biocare AB, Nobel Biocare Holding AG completes the offer to acquire all the outstanding shares of Nobel Biocare AB. The board of Nobel Biocare Holding AG has therefore decided to initiate a delisting of Nobel Biocare AB's shares (UNOB.ST) from the Stockholm Stock Exchange (Stockholmsbörsen), with last trading day 18th of July 2002. The compulsory acquisition procedure to acquire the remaining approximately 1% of the

Nobel Biocare Holding AG: First trading day in Zurich and Stockholm for new share

Nobel Biocare Holding AG: First trading day in Zurich and Stockholm for new share On Monday, June 24, 2002, the shares of Nobel Biocare Holding AG were introduced on the Zurich and Stockholm stock exchanges and trading started this morning. This follows the successful share exchange offer from Nobel Biocare Holding AG to the shareholders of Nobel Biocare AB. The new shares are being quoted on the Main Board of the SWX Swiss Exchange and on the A- list, Most traded list, on the Stockholm Stock Exchange. In a comment, Heliane Canepa, CEO of Nobel Biocare, says: "The successful implementation

Nobel Biocare Holding AG holds 94.6 per cent of Nobel Biocare AB and completes the public offer

Nobel Biocare Holding AG holds 94.6 per cent of Nobel Biocare AB and completes the public offer The public offer by Nobel Biocare Holding AG to acquire all the outstanding shares in Nobel Biocare AB has been accepted to such an extent that Nobel Biocare Holding AG now controls approximately 94.6 per cent of the shares and votes in Nobel Biocare AB. All the conditions for Nobel Biocare Holding AG's public offer as stated in the offer document dated 27 May 2002 have therefore been met and Nobel Biocare Holding AG will subsequently complete the public offer. Settlement for those who have

Nobel Biocare Holding AG - New holding structure for Nobel Biocare AB

Nobel Biocare Holding AG - New holding structure for Nobel Biocare AB Share exchange offer for all outstanding shares of Nobel Biocare AB · Nobel Biocare Holding AG makes a share exchange offer to the shareholders of Nobel Biocare AB. One new share of Nobel Biocare Holding AG is offered for every share of Nobel Biocare AB. · The new holding structure of the Nobel Biocare Group will be implemented through the announced share exchange offer. · The Board of Directors of Nobel Biocare AB unanimously recommends its shareholders to accept the share exchange offer. · The Offer Document in relation

Nobel Biocare Annual General Meeting 2002

Nobel Biocare Annual General Meeting 2002 The Annual General Meeting on April 24, 2001, approved a dividend of SEK 3.00 or a total of SEK 76,065,000. The record day for this dividend will be 29 April 2002. Payment is expected to be made by VPC AB (the Swedish Securities Registration Centre) on 3 May 2002. The following board members were re-elected: Ernst Thomke, Ernst Zaengerle, Jan Kvarnström and Jan Ekberg. Hans-Jörg Graf was elected as new board member. Heliane Canepa had declined re-election as she is the CEO and President of the company. KPMG Bohlins AB with Thomas Thiel as main

New holding structure

PRESS RELEASE · Establishing new Swiss holding structure · No change to Nobel Biocare's operations · Shares to be listed in Zurich and in Stockholm The Board of Directors of Nobel Biocare has decided to initiate the establishment of a new Swiss holding structure to support the company's continued efforts to increase profitability, to sustain long-term market leadership and to create value for the shareholders. Nobel Biocare has over the last few years developed into an increasingly international group with 95 per cent of its sales generated outside Sweden, 71 per cent of its employees based

Full Year Report 2001

Full Year Report 2001 (Gothenburg, 7 February 2002)The Nobel Biocare Group Sales increased by 26% to SEK 2 663.2 million (2 109.5). Sales in the fourth quarter amounted to SEK 754.1 million (634.8). · Operating income amounted to SEK 363.7 million (289.6). Operating income before non-recurring items amounted to SEK 430.1 million (267.3). The year-on-year currency effects were positive, SEK 23 million. Operating income before non-recurring items in the fourth quarter amounted to SEK 136.1 million (123.7). · Cash flow from current operations amounted to SEK 684.4 million (263.8). · Earnings

Nobel Biocare takes full control of Procera-Sandvik - strengthens its position as world leader of innovative dental sol

Nobel Biocare takes full control of Procera-Sandvik - strengthens its position as world leader of innovative dental solutions Nobel Biocare is the world leader in dental implants. In an agreement with Sandvik AB, Nobel Biocare has acquired Sandvik's 50% share of the dental technology company Procera-Sandvik AB. Nobel Biocare is thereby strengthening its market position by getting full control of the development and production of individualized ceramic prosthetics for both conventional and implant dentistry. "By taking full control of the Procera business we can utilize our world- wide and

Profitability targets for Nobel Biocare announced

Profitability targets for Nobel Biocare announced At today's analyst meeting in Stockholm, Heliane Canepa, President of Nobel Biocare, announced targets for Nobel Biocare for 2002. The plan includes the following priorities: Profitability Increasing the EBITA-margin for Dental Implants from 19% (YTD 2001) to above 24% for FY 2002. The plan for 2002 contains a gross profit improvement through the carry-over effect of the current complexity reduction program and further efficiency gains in purchasing, manufacturing and logistics. In addition, operating expenses will be cut by setting cost

There are no items matching the current filter
There are no more items matching the current filter
Back to top